18F-fluciclovine PET or PSMA PET for prostate cancer imaging?

Data from a new study suggests that prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging is superior to 18F-fluciclovine PET for detecting biochemical recurrence in men with prostate cancer. However, whether one of these radiotracers improves patient survival over the other is unknown and further research is needed to determine which has the greater effect.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Simmons, M. N., Stephenson, A. J. & Klein, E. A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur. Urol. 51, 1175–1184 (2007).

  2. 2.

    Lindenberg, M. L. et al. Imaging locally advanced, recurrent, and metastatic prostate cancer: a review. JAMA Oncol. 3, 1415–1422 (2017).

  3. 3.

    Mena, E., Lindenberg, L. M. & Choyke, P. L. New targets for PET molecular imaging of prostate cancer. Semin. Nucl. Med. 49, 326–336 (2019).

  4. 4.

    US Food & Drug Administration. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer. FDA (2016).

  5. 5.

    Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019).

  6. 6.

    Savir-Baruch, B. et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin. Nucl. Med. 43, 909–917 (2018).

  7. 7.

    Tan N. et al. Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. J. Urol. 202, 231–240 (2019).

Download references

Author information

Correspondence to Baris Turkbey.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Turkbey, B., Choyke, P.L. 18F-fluciclovine PET or PSMA PET for prostate cancer imaging?. Nat Rev Urol 17, 9–10 (2020).

Download citation